ORATOR2 trial: what clinicians have said so far
Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer
- NCT03210103 ↗
- Active, not recruiting
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Deep size, estimated: 301+ verified statements once built
We haven't built an HCP commentary report on ORATOR2 (HPV-associated oropharyngeal squamous cell carcinoma; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 38 most recent indexed sources
Automated from the 38 newest of 48 indexed sources (Mar 2019 – Oct 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- How surgeon credentialing and surgical outcomes in the transoral surgery arm compare with E3311 and MC1675
- Whether early closure leaves the trial too small and immature to compare oncologic outcomes between arms
- Whether the radiotherapy arm's event rate is consistent with real-world outcomes outside the trial
- Whether the trial should end routine transoral surgery as a de-escalation approach in HPV-positive disease
Indexed commentary on ORATOR2 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 46 posts on X, typically up to 202 once built | |
| 1 YouTube video, typically up to 4 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery (ORATOR II)
- Phase
- Phase not applicable
- Status
- Active, not recruiting
- Conditions
- Oropharyngeal Cancer
- Interventions
- Radiation; Transoral Surgery (TOS) + Neck Dissection
- Arms
- Arm 1, Radiation +/- Chemotherapy · Active comparator
- Arm 2, TOS + Neck Dissection · Experimental
- Enrollment
- 61
- Primary outcomes
- Overall Survival
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Start
- Jan 26, 2018
- Primary completion
- Aug 15, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT03210103 · updated Jan 28, 2026
Publications
linked from the registry- Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, Hier M, Richardson K, Mlynarek A, Johnson-Obaseki S, Gaudet M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Kwan K, Theurer J, Bahig H, Christopoulos A, Mendez LC, Sathya J, Hammond JA, Read N, Venkatesan V, Fung K, Nichols AC. Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial. Eur J Cancer. 2025 May 2;220:115343. doi: 10.1016/j.ejca.2025.115343. Epub 2025 Mar 10. PubMed 40121836
- Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, Hier M, Sultanem K, Richardson K, Mlynarek A, Johnson-Obaseki S, Odell M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Krishnan S, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Wehrli B, Kwan K, Theurer J, Sathya J, Hammond JA, Read N, Venkatesan V, MacNeil SD, Fung K, Nichols AC. Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022 Jun 1;8(6):1-7. doi: 10.1001/jamaoncol.2022.0615. PubMed 35482348
- Nichols AC, Lang P, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Fung K, de Almeida JR, Bayley A, Goldstein DP, Eskander A, Husain Z, Bahig H, Christopoulous A, Hier M, Sultanem K, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Mendez A, Winquist E, Read N, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Corsten M, Rajaraman M, Johnson-Obaseki S, Eapen L, Odell M, Chandarana S, Banerjee R, Dort J, Matthews TW, Hart R, Kerr P, Dowthwaite S, Gupta M, Zhang H, Wright J, Parker C, Wehrli B, Kwan K, Theurer J, Palma DA. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial. BMC Cancer. 2020 Feb 14;20(1):125. doi: 10.1186/s12885-020-6607-z. PubMed 32059705